Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

Enhertu demonstrated median progression-free survival of 14.3 months as a first-line treatment for patients with HER2-mutant advanced non-small cell lung cancer in the DESTINY-Lung04 trial. The result supports the drug's potential expansion in a targeted lung-cancer setting and is a positive clinical-development catalyst for its developers.